Therapeutic burden in hidradenitis suppurativa: a cross‐sectional study of 557 patients
International Journal of Dermatology · 2025
DOI: 10.1111/ijd.17517 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Dermatology, 2025. Verfasst von Sofía Haselgruber und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Virgen de las Nieves, Servicio de Dermatología, Granada, Spain. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Therapeutic burden (TB) has been identified as a potential predictor of response to biologic therapy in hidradenitis suppurativa (HS). We aim to analyze the determinants of TB in real‐world clinical settings among HS patients to explain this concept and its utility as an additional tool for guiding therapeutic decision‐making.
Methods
We conducted a cross‐sectional study including all consecutive HS patients attending a specialized HS clinic between 2017 and 2024. The primary variable was TB, defined as the cumulative sum of prior systemic treatment cycles and surgical interventions for HS. We analyzed whether sociodemographic or clinical factors were associated with a higher TB.
Results
We included 557 HS patients. Of these, 50.81% were women, and the mean age was 41.87 (14.19) years. Most patients (62.30%) were referred from general dermatology consultations. The mean disease duration was 17.52 (11.51) years. Regarding disease severity, 46.50% presented with Hurley II, and 42.19% had an IHS‐4 score between 4 and 10. Before their baseline visit, 9.70% of patients had received biological therapy, mostly adalimumab (88.89%). The mean TB was 2.42 (2.25) systemic medical and/or surgical interventions. Referral from general dermatology or other hospital departments, older age, longer disease duration, greater HS severity, presence of pilonidal sinus, and prior biological therapy were significantly associated with higher TB.
Conclusions
Our findings suggest that TB comprehensively captures HS severity and progression factors. This metric could prove valuable in aiding decision‐making for HS patients by indicating when a change in therapy might be necessary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Universitario Virgen de las Nieves, Servicio de Dermatología, Granada, Spain.
- Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.
- European Hidradenitis Suppurativa Foundation e.V, Dessau, Germany.
- Facultad de Medicina, Universidad de Granada, Granada, Spain.
ORCID-Profile: Sofía Haselgruber, Carlos Cuenca-Barrales, Alejandro Molina-Leyva
Zitieren
APA
Haselgruber, S., Muñoz-Barba, D., Leon-Pérez, F. J., Cuenca-Barrales, C., Arias-Santiago, S., & Molina-Leyva, A. (2025). Therapeutic burden in hidradenitis suppurativa: a cross‐sectional study of 557 patients. International Journal of Dermatology. https://doi.org/10.1111/ijd.17517
Vancouver
Haselgruber S, Muñoz-Barba D, Leon-Pérez FJ, Cuenca-Barrales C, Arias-Santiago S, Molina-Leyva A. Therapeutic burden in hidradenitis suppurativa: a cross‐sectional study of 557 patients. International Journal of Dermatology. 2025. doi:10.1111/ijd.17517
BibTeX
@article{Haselgruber2025,
author = {Haselgruber, Sofía and Muñoz-Barba, Daniel and Leon-Pérez, Francisco Javier and Cuenca-Barrales, Carlos and Arias-Santiago, Salvador and Molina-Leyva, Alejandro},
title = {Therapeutic burden in hidradenitis suppurativa: a cross‐sectional study of 557 patients},
journal = {International Journal of Dermatology},
year = {2025},
doi = {10.1111/ijd.17517}
}
EUVIMED